|
1
|
Dunn GP, Rinne ML, Wykosky J, Genovese G,
Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, et
al: Emerging insights into the molecular and cellular basis of
glioblastoma. Genes Dev. 26:756–784. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Radner H, Blümcke I, Reifenberger G and
Wiestler OD: The new WHO classification of tumors of the nervous
system 2000. Pathology and genetics. Pathologe. 23:260–283. 2002.In
German. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qi J, Yang H, Wang X and Tu Y: The
progress in molecular biomarkers of gliomas. Cancer Transl Med.
2:125–129. 2016. View Article : Google Scholar
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Athanassiou H, Synodinou M, Maragoudakis
E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G,
Beroukas K and Karageorgis P: Randomized phase II study of
temozolomide and radiotherapy compared with radiotherapy alone in
newly diagnosed glioblastoma multiforme. J Clin Oncol.
23:2372–2377. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nagane M, Kobayashi K, Ohnishi A, Shimizu
S and Shiokawa Y: Prognostic significance of O6-methylguanine-DNA
methyltransferase protein expression in patients with recurrent
glioblastoma treated with temozolomide. Jpn J Clin Oncol.
37:897–906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Groves MD, Puduvalli VK, Hess KR, Jaeckle
KA, Peterson P, Yung WK and Levin VA: Phase II trial of
temozolomide plus the matrix metalloproteinase inhibitor,
marimastat, in recurrent and progressive glioblastoma multiforme. J
Clin Oncol. 20:1383–1388. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bektas M, Johnson SP, Poe WE, Bigner DD
and Friedman HS: A sphingosine kinase inhibitor induces cell death
in temozolomide resistant glioblastoma cells. Cancer Chemother
Pharmacol. 64:1053–1058. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bocangel DB, Finkelstein S, Schold SC,
Bhakat KK, Mitra S and Kokkinakis DM: Multifaceted resistance of
gliomas to temozolomide. Clin Cancer Res. 8:2725–2734.
2002.PubMed/NCBI
|
|
10
|
Gubbay J, Collignon J, Koopman P, Capel B,
Economou A, Münsterberg A, Vivian N, Goodfellow P and Lovell-Badge
R: A gene mapping to the sex-determining region of the mouse Y
chromosome is a member of a novel family of embryonically expressed
genes. Nature. 346:245–250. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
de la Rocha AM, Sampron N, Alonso MM and
Matheu A: Role of SOX family of transcription factors in central
nervous system tumors. Am J Cancer Res. 4:312–324. 2014.PubMed/NCBI
|
|
12
|
Wagner T, Wirth J, Meyer J, Zabel B, Held
M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E, et al:
Autosomal sex reversal and campomelic dysplasia are caused by
mutations in and around the SRY-related gene SOX9. Cell.
79:1111–1120. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Foster JW, Dominguez-Steglich MA, Guioli
S, Kwok C, Weller PA, Stevanović M, Weissenbach J, Mansour S, Young
ID, Goodfellow PN, et al: Campomelic dysplasia and autosomal sex
reversal caused by mutations in an SRY-related gene. Nature.
372:525–530. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang SS, Fang WT, Hou YH, Huang SF, Yen
BL, Chang JL, Li SM, Liu HP, Liu YL, Huang CT, et al: Upregulation
of SOX9 in lung adenocarcinoma and its involvement in the
regulation of cell growth and tumorigenicity. Clin Cancer Res.
16:4363–4373. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Capaccione KM, Hong X, Morgan KM, Liu W,
Bishop JM, Liu L, Markert E, Deen M, Minerowicz C, Bertino JR, et
al: Sox9 mediates Notch1-induced mesenchymal features in lung
adenocarcinoma. Oncotarget. 5:3636–3650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chakravarty G, Rider B and Mondal D:
Cytoplasmic compartmentalization of SOX9 abrogates the growth
arrest response of breast cancer cells that can be rescued by
trichostatin A treatment. Cancer Biol Ther. 11:71–83. 2011.
View Article : Google Scholar
|
|
17
|
Matheu A, Collado M, Wise C, Manterola L,
Cekaite L, Tye AJ, Canamero M, Bujanda L, Schedl A, Cheah KS, et
al: Oncogenicity of the developmental transcription factor Sox9.
Cancer Res. 72:1301–1315. 2012. View Article : Google Scholar :
|
|
18
|
Raspaglio G, Petrillo M, Martinelli E, Li
Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei
S, Zannoni GF, et al: Sox9 and Hif-2α regulate TUBB3 gene
expression and affect ovarian cancer aggressiveness. Gene.
542:173–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thomsen MK, Ambroisine L, Wynn S, Cheah
KS, Foster CS, Fisher G, Berney DM, Møller H, Reuter VE, Scardino
P, et al Transatlantic Prostate Group: SOX9 elevation in the
prostate promotes proliferation and cooperates with PTEN loss to
drive tumor formation. Cancer Res. 70:979–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang L, He S, Yuan J, Mao X, Cao Y, Zong
J, Tu Y and Zhang Y: Oncogenic role of SOX9 expression in human
malignant glioma. Med Oncol. 29:3484–3490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Swartling FJ, Ferletta M, Kastemar M,
Weiss WA and Westermark B: Cyclic GMP-dependent protein kinase II
inhibits cell proliferation, Sox9 expression and Akt
phosphorylation in human glioma cell lines. Oncogene. 28:3121–3131.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
23
|
Swartling FJ, Savov V, Persson AI, Chen J,
Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, et
al: Distinct neural stem cell populations give rise to disparate
brain tumors in response to N-MYC. Cancer Cell. 21:601–613. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang G, Lunardi A, Zhang J, Chen Z, Ala U,
Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, et
al: Zbtb7a suppresses prostate cancer through repression of a
Sox9-dependent pathway for cellular senescence bypass and tumor
invasion. Nat Genet. 45:739–746. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang YJ, Xu F, Zhang YJ, Li HB, Han JC
and Li L: miR-206 inhibits non small cell lung cancer cell
proliferation and invasion by targeting SOX9. Int J Clin Exp Med.
8:9107–9113. 2015.PubMed/NCBI
|
|
26
|
Larsimont JC, Youssef KK, Sánchez-Danés A,
Sukumaran V, Defrance M, Delatte B, Liagre M, Baatsen P, Marine JC,
Lippens S, et al: Sox9 controls self-renewal of oncogene targeted
cells and links tumor initiation and invasion. Cell Stem Cell.
17:60–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao J, Zhang JY, Li YH and Ren F:
Decreased expression of SOX9 indicates a better prognosis and
inhibits the growth of glioma cells by inducing cell cycle arrest.
Int J Clin Exp Pathol. 8:10130–10138. 2015.PubMed/NCBI
|
|
28
|
Ling S, Chang X, Schultz L, Lee TK, Chaux
A, Marchionni L, Netto GJ, Sidransky D and Berman DM: An
EGFR-ERK-SOX9 signaling cascade links urothelial development and
regeneration to cancer. Cancer Res. 71:3812–3821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haller R, Schwanbeck R, Martini S, Bernoth
K, Kramer J, Just U and Rohwedel J: Notch1 signaling regulates
chondrogenic lineage determination through Sox9 activation. Cell
Death Differ. 19:461–469. 2012. View Article : Google Scholar :
|
|
30
|
Blache P, van de Wetering M, Duluc I,
Domon C, Berta P, Freund JN, Clevers H and Jay P: SOX9 is an
intestine crypt transcription factor, is regulated by the Wnt
pathway, and represses the CDX2 and MUC2 genes. J Cell Biol.
166:37–47. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lafont JE, Talma S, Hopfgarten C and
Murphy CL: Hypoxia promotes the differentiated human articular
chondrocyte phenotype through SOX9-dependent and -independent
pathways. J Biol Chem. 283:4778–4786. 2008. View Article : Google Scholar
|
|
32
|
Bastide P, Darido C, Pannequin J, Kist R,
Robine S, Marty-Double C, Bibeau F, Scherer G, Joubert D, Hollande
F, et al: Sox9 regulates cell proliferation and is required for
Paneth cell differentiation in the intestinal epithelium. J Cell
Biol. 178:635–648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ikegami D, Akiyama H, Suzuki A, Nakamura
T, Nakano T, Yoshikawa H and Tsumaki N: SOX9 sustains chondrocyte
survival and hypertrophy in part through Pik3ca-Akt pathways.
Development. 138:1507–1519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Linz U: Commentary on effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 2009.10:459–466. View Article : Google Scholar
Cancer. 116:1844–1846. 2010. View Article : Google Scholar
|
|
35
|
Yu XZ, Han GK, Yang WT, Li ZY and Jin F:
Effect of temozolomide on cell proliferation and migration ability
of glioma TJ905 cells. J Xinxiang Medical University. 32:111–114.
2015.
|
|
36
|
Liu N, Zhang L, Wang Z, Cheng Y, Zhang P,
Wang X, Wen W, Yang H, Liu H, Jin W, et al: MicroRNA-101 inhibits
proliferation, migration and invasion of human glioblastoma by
targeting SOX9. Oncotarget. 8:19244–19254. 2017.
|
|
37
|
Lou Y, McDonald PC, Oloumi A, Chia S,
Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D,
et al: Targeting tumor hypoxia: Suppression of breast tumor growth
and metastasis by novel carbonic anhydrase IX inhibitors. Cancer
Res. 71:3364–3376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Song L, Li D, Gu Y, Wen ZM, Jie J, Zhao D
and Peng LP: MicroRNA-126 targeting PIK3R2 inhibits NSCLC A549 cell
proliferation, migration, and invasion by regulation of
PTEN/PI3K/AKT pathway. Clin Lung Cancer. 17:e65–e75. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gaspar N, Marshall L, Perryman L, Bax DA,
Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis
RM, et al: MGMT-independent temozolomide resistance in pediatric
glioblastoma cells associated with a PI3-kinase-mediated HOX/stem
cell gene signature. Cancer Res. 70:9243–9252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pyko IV, Nakada M, Sabit H, Teng L,
Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS and
Hamada J: Glycogen synthase kinase 3β inhibition sensitizes human
glioblastoma cells to temozolomide by affecting O6-methylguanine
DNA methyltransferase promoter methylation via c-Myc signaling.
Carcinogenesis. 34:2206–2217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jarskog LF, Selinger ES, Lieberman JA and
Gilmore JH: Apoptotic proteins in the temporal cortex in
schizophrenia: High Bax/Bcl-2 ratio without caspase-3 activation.
Am J Psychiatry. 161:109–115. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kobayashi T, Masumoto J, Tada T, Nomiyama
T, Hongo K and Nakayama J: Prognostic significance of the
immunohistochemical staining of cleaved caspase-3, an activated
form of caspase-3, in gliomas. Clin Cancer Res. 13:3868–3874. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed
K and Gallo JM: Biochemical changes associated with a
multidrug-resistant phenotype of a human glioma cell line with
temozolomide-acquired resistance. Biochem Pharmacol. 63:1219–1228.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Das A, Banik NL, Patel SJ and Ray SK:
Dexamethasone protected human glioblastoma U87MG cells from
temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and
preventing proteolytic activities. Mol Cancer. 3:362004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stoeckl S, Goettl C, Grifka J and Graessel
S: In vitro gene knockdown of SOX9 in rat MSC affects Bcl2
expression. Eur J Cell. 89(Suppl 1): S142010.
|
|
46
|
Shao J, Wang L, Zhong C, Qi R and Li Y:
AHSA1 regulates proliferation, apoptosis, migration, and invasion
of osteosarcoma. Biomed Pharmacother. 77:45–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sun GG, Wang YD, Cui DW, Cheng YJ and Hu
WN: EMP1 regulates caspase-9 and VEGFC expression and suppresses
prostate cancer cell proliferation and invasion. Tumour Biol.
35:3455–3462. 2014. View Article : Google Scholar
|
|
48
|
Jason CP, Chaudhary J and Evans A:
Abstract LB-6: bHLH transcription factor Id4 plays a regulatory
role in cell cycle control, apoptosis, and senescence in
androgen-insensitive prostate cancer. Cancer Res. 70(Suppl):
321–327. 2010. View Article : Google Scholar
|
|
49
|
Chen D, Zuo D, Luan C, Liu M, Na M, Ran L,
Sun Y, Persson A, Englund E, Salford LG, et al: Glioma cell
proliferation controlled by ERK activity-dependent surface
expression of PDGFRA. PLoS One. 9:e872812014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Svastová E, Zilka N, Zat'ovicová M,
Gibadulinová A, Ciampor F, Pastorek J and Pastoreková S: Carbonic
anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via
interaction with β-catenin. Exp Cell Res. 290:332–345. 2003.
View Article : Google Scholar
|
|
51
|
Dorai T, Sawczuk IS, Pastorek J, Wiernik
PH and Dutcher JP: The role of carbonic anhydrase IX overexpression
in kidney cancer. Eur J Cancer. 41:2935–2947. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ebos JM, Lee CR and Kerbel RS: Tumor and
host-mediated pathways of resistance and disease progression in
response to antiangiogenic therapy. Clin Cancer Res. 15:5020–5025.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
McLendon R, Friedman A, Bigner D, et al
Cancer Genome Atlas Research Network: Comprehensive genomic
characterization defines human glioblastoma genes and core
pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar
|
|
54
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Franco DG, Moretti IF and Marie SK:
Abstract 1498: Melatonin inhibits mitochondrial transcription
factor A expression in glioblastoma U87MG cell culture inducing an
anti-tumorigenic effect. Cancer Res. 77(Supplement): 14982017.
View Article : Google Scholar
|
|
56
|
Lan YL, Wang X, Xing JS, Yu ZL, Lou JC, Ma
XC and Zhang B: Anti-cancer effects of dopamine in human glioma:
Involvement of mitochondrial apoptotic and anti-inflammatory
pathways. Oncotarget. 8:88488–88500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Han MZ, Xu R, Xu YY, Zhang X, Ni SL, Huang
B, Chen AJ, Wei YZ, Wang S, Li WJ, et al: TAGLN2 is a candidate
prognostic biomarker promoting tumorigenesis in human gliomas. J
Exp Clin Cancer Res. 36:1552017. View Article : Google Scholar : PubMed/NCBI
|
